GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Total Liabilities

Renovacor (Renovacor) Total Liabilities : $15.03 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor Total Liabilities?

Renovacor's Total Liabilities for the quarter that ended in Sep. 2022 was $15.03 Mil.

Renovacor's quarterly Total Liabilities declined from Mar. 2022 ($11.37 Mil) to Jun. 2022 ($7.37 Mil) but then increased from Jun. 2022 ($7.37 Mil) to Sep. 2022 ($15.03 Mil).

Renovacor's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.19 Mil) and increased from Dec. 2020 ($0.19 Mil) to Dec. 2021 ($27.46 Mil).


Renovacor Total Liabilities Historical Data

The historical data trend for Renovacor's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Total Liabilities Chart

Renovacor Annual Data
Trend Dec20 Dec21
Total Liabilities
0.19 27.46

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Liabilities Get a 7-Day Free Trial Premium Member Only 34.56 27.46 11.37 7.37 15.03

Renovacor Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Renovacor's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.034+(0+23.421
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=27.46

Total Liabilities=Total Assets (A: Dec. 2021 )-Total Equity (A: Dec. 2021 )
=80.999-53.544
=27.46

Renovacor's Total Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.433+(0.265+6.336
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=15.03

Total Liabilities=Total Assets (Q: Sep. 2022 )-Total Equity (Q: Sep. 2022 )
=57.742-42.708
=15.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renovacor Total Liabilities Related Terms

Thank you for viewing the detailed overview of Renovacor's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovacor (Renovacor) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines